search
Back to results

Stent Retriever Versus Contact Aspiration in Irregular Occlusion Phenotype (STRIPE)

Primary Purpose

Stroke, Acute

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
stent retriever thrombectomy
contact aspiration thrombectomy
Sponsored by
Hopital Foch
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Stroke, Acute

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age ≥ 18 years
  • M1-Middle Cerebral Artery occlusion
  • Eligible for mechanical thrombectomy: groin puncture performed within 24 hours from the first symptoms or from the last time the patient was seen normal.
  • Presence of a mismatch on Magnetic resonance imaging MRI or CT (computed tomography) scan
  • Baseline mRS <2
  • Irregular occlusion phenotype on the first angiographic run
  • Informed consent obtained from the patients/his proxy or following an emergency procedure
  • Being covered by a national health insurance

Exclusion Criteria:

  • Isolated M2 occlusions
  • Clinical history, past imaging or clinical judgment suggesting underlying intracranial stenosis
  • Severe contrast medium allergy or absolute contraindication to use of iodinated products
  • Patients with severe or fatal comorbidities that will likely prevent improvement or follow-up, or that will render the procedure unlikely to benefit the patient
  • Angiographic evidence of carotid dissection or tandem cervical occlusion or stenosis requiring treatment
  • Pregnancy (urine or serum beta HCG test for women of child-bearing potential)
  • Patient benefiting from a legal protection (guardianship or curatorship)
  • Being deprived of liberty

Sites / Locations

  • Chu Bordeaux
  • CHU Montpellier
  • Chru Nancy
  • Chu NantesRecruiting
  • APHP - Pitié SalpêtrièreRecruiting
  • Fondation Adolphe de Rothschild
  • CHU de Reims
  • Hôpital FOCH
  • CHU de Tours

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

Stent retriever

Contact aspiration

Arm Description

The patients will be treated to receive stent retriever (with or without contact aspiration) first line thrombectomy (experimental arm).

The patients will be treated to receive direct contact aspiration first line thrombectomy (control arm)

Outcomes

Primary Outcome Measures

Rate of favorable functional outcome at 90-day defined by a Modified Rankin Scale (mRS) 0-2
mRS is evaluated between 0 to 6. A score of 0 indicates that there is no disability and a score of 6 indicates death

Secondary Outcome Measures

Rate of patients with first pass effect (FPE) defined as mTICI 2c/3 after first device maneuver
The definition of FPE: single pass/use of the device, (2) complete revascularization of the large vessel occlusion and its downstream territory (mTICI 3), and (3) no use of rescue therapy
Rates of patients with complete (mTICI 3), perfect (mTICI 2c/3) and successful reperfusion (mTICI 2b/3) at the end of endovascular procedure
mTICI (modified Thrombolysis In Cerebral Infarction ) score equals to 3 after the first line thrombectomy and at the end of endovascular. mTICI score is evaluated between 0-3 : 0 a complete obstruction of the artery and 3 indicates a complete reperfusion
Time from groin puncture to achieve the maximum recanalization
The time between the groin puncture and the maxiamum recanalization will be assessed
Rate of patients who will require less than 2 device pass
Rate of patients with rescue therapy use
Degree of disability assessed by overall distribution of the mRS at 90 days and one year (shift analysis combining scores of 5 and 6)
Rate of all-cause mortality at 90 day and one year
24 hours change in NIHSS from baseline defined as the difference between NIHSS score at 24 hours and NIHSS score at admission
NIHSS (National Institutes of Health Stroke Scale) score is evaluated between 0-42 0 is normal and 42 maximal gravity
Incidence of intracerebral haemorrhage (ICH), parenchymal hematoma, symptomatic ICH, on brain imaging (Magnetic resonance imaging MRI or CT (computed tomography) scan) at 24 hours after thrombectomy (according to ECASS3 classification)
ECASS III (European Cooperative Acute Stroke Study) classification : Hemorrhage infarction type 1 (HI1) Hemorrhage infarction type 2 (HI2) Parenchymal hematoma type 1 (PH1) Parenchymal hematoma type 2 (PH2)
Incidence of procedure-related complications such as arterial perforation or dissection, embolization in new territory

Full Information

First Posted
October 24, 2022
Last Updated
February 27, 2023
Sponsor
Hopital Foch
search

1. Study Identification

Unique Protocol Identification Number
NCT05595876
Brief Title
Stent Retriever Versus Contact Aspiration in Irregular Occlusion Phenotype
Acronym
STRIPE
Official Title
Stent Retriever Versus Contact Aspiration in Irregular Occlusion Phenotype, a Novel Approach in the Endovascular Treatment of Acute Ischemic Stroke: the STRIPE Randomized Trial.
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 19, 2022 (Actual)
Primary Completion Date
February 1, 2025 (Anticipated)
Study Completion Date
November 1, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hopital Foch

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Patients with a clinico-neuroradiological mismatch pattern shown on the magnetic resonance imaging/Computed Tomography in the acute phase of stroke are more likely to benefit from reperfusion, are suitable candidates for endovascular therapy, and have a better clinical prognosis. The ASTER Trial showed similar results between stent-retrievers and contact aspiration concerning the recanalization grade in anterior circulation occlusions. However, we still observe late and futile recanalizations, secondary either to extended ischemic lesions at baseline, long-time procedures or intraprocedural complications. The First Pass Effect that is the complete/nearly complete recanalization after the first maneuver, independently on the technique used, has been strongly associated with better clinical outcomes . In a recent paper we proposed a novel approach to identify those cases that could be treated with a specific technique (stent-retriever) with higher chances to achieve a complete or nearly complete recanalization, with lower procedure times and lower complication rates. This approach is focused on the identification of a regular or irregular phenotype of the occlusion site in patients with an M1-Middle Cerebral Artery occlusion. The phenotype is defined as "regular" whether the profile of the occlusion is abruptly cut without any irregularity and as "irregular" if any irregularity of the profile of the occlusion is observed. One of the hypotheses that could explain these results could be related to the composition of the clot : a soft and less organized clot could be more easily flattened by the pulsatile flow and therefore determine a regular aspect of the occlusion. A more solid and organized clot would, on the contrary, maintain an irregular profile because it would not be flattened by the blood flow and the contrast medium could highlight the irregularities of the proximal face of the clot. The latter could be a favorable target for the use of a stent-retriever since the interaction between a solid clot and the struts of the stent could increase the chance to retrieve the clot. Therefore, we propose this randomized controlled trial to assess the superiority of stent-retrievers compared to contact aspiration in the treatment of irregular phenotype occlusions of the M1-Middle Cerebral Artery.
Detailed Description
Statistical analyses will be independently performed by the Biostatistics Department of University of Lille under the responsibility of Julien Labreuche. Data will be analyzed using the SAS software (SAS Institute Inc, Cary, NC, USA). A detailed statistical analysis plan will be written and finalized prior to the database lock. Baseline characteristics will be described for each group. Quantitative variables will be expressed as mean (standard deviation) or median (interquartile range) for non-Gaussian distribution. Qualitative variables will be expressed as frequencies and percentages. Normality of distribution will be assessed graphically and using the Shapiro-Wilk test. All applicable statistical tests will be 2-sided and no correction for multiple comparisons will be applied; all secondary objectives will be considered as exploratory and results were reported with only effect size estimates with their confidence intervals (CIs). All CIs presented will be 95%CI and 2-sided. The final report will be written, based on the CONSORT statement recommendations.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stroke, Acute

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Masking Description
The angiographic outcomes will be assessed by a centralized Core Laboratory, not involved in patient management.
Allocation
Randomized
Enrollment
356 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Stent retriever
Arm Type
Experimental
Arm Description
The patients will be treated to receive stent retriever (with or without contact aspiration) first line thrombectomy (experimental arm).
Arm Title
Contact aspiration
Arm Type
Sham Comparator
Arm Description
The patients will be treated to receive direct contact aspiration first line thrombectomy (control arm)
Intervention Type
Procedure
Intervention Name(s)
stent retriever thrombectomy
Intervention Description
The technique used should be in accordance with the device IFU (instructions for use). A large bore access guide catheter possible is mandatory. A suitable delivery microcatheter is navigated over a microwire across the occlusion. A control superselective angiogram may be used to document the extent of occlusion and thrombus. The stent is left in place according to the internal practice of each participating center before the withdrawal. Any CE (european compliance)-marked stent retriever device is then deployed across the occlusion. A contact aspiration large bore catheter can be used in association with the stent retriever. A minimum of 3 attempts with Stent retriever should be performed. A revascularization score will be recorded after each device attempt.
Intervention Type
Procedure
Intervention Name(s)
contact aspiration thrombectomy
Intervention Description
A 0.021 to 0.027 inch inner lumen microcatheter with a 0.014 to 0.016 inch microwire inside is then introduced into a large-bore aspiration catheter and this construct is introduced into the long sheath as a unit. A large bore balloon guide catheter has to be placed into the cervical internal carotid artery. The microcatheter is then advanced close to the thrombus and the large-bore aspiration catheter is advanced as close to the proximal aspect of the thrombus as possible. A control angiogram may be used to document the extent of occlusion and thrombus. After a 3 min waiting period, the large-bore aspiration catheter is connected to a continuous aspiration from the dedicated aspiration pump while simultaneously advancing the aspiration catheter up to the face of the thrombus. Once thrombus will be close to the aspiration catheter, then the system will carefully removed as a unit under continuous aspiration.
Primary Outcome Measure Information:
Title
Rate of favorable functional outcome at 90-day defined by a Modified Rankin Scale (mRS) 0-2
Description
mRS is evaluated between 0 to 6. A score of 0 indicates that there is no disability and a score of 6 indicates death
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Rate of patients with first pass effect (FPE) defined as mTICI 2c/3 after first device maneuver
Description
The definition of FPE: single pass/use of the device, (2) complete revascularization of the large vessel occlusion and its downstream territory (mTICI 3), and (3) no use of rescue therapy
Time Frame
24 hours
Title
Rates of patients with complete (mTICI 3), perfect (mTICI 2c/3) and successful reperfusion (mTICI 2b/3) at the end of endovascular procedure
Description
mTICI (modified Thrombolysis In Cerebral Infarction ) score equals to 3 after the first line thrombectomy and at the end of endovascular. mTICI score is evaluated between 0-3 : 0 a complete obstruction of the artery and 3 indicates a complete reperfusion
Time Frame
24 hours
Title
Time from groin puncture to achieve the maximum recanalization
Description
The time between the groin puncture and the maxiamum recanalization will be assessed
Time Frame
24 hours
Title
Rate of patients who will require less than 2 device pass
Time Frame
24 hours
Title
Rate of patients with rescue therapy use
Time Frame
24 hours
Title
Degree of disability assessed by overall distribution of the mRS at 90 days and one year (shift analysis combining scores of 5 and 6)
Time Frame
12 months
Title
Rate of all-cause mortality at 90 day and one year
Time Frame
12 months
Title
24 hours change in NIHSS from baseline defined as the difference between NIHSS score at 24 hours and NIHSS score at admission
Description
NIHSS (National Institutes of Health Stroke Scale) score is evaluated between 0-42 0 is normal and 42 maximal gravity
Time Frame
24 hours
Title
Incidence of intracerebral haemorrhage (ICH), parenchymal hematoma, symptomatic ICH, on brain imaging (Magnetic resonance imaging MRI or CT (computed tomography) scan) at 24 hours after thrombectomy (according to ECASS3 classification)
Description
ECASS III (European Cooperative Acute Stroke Study) classification : Hemorrhage infarction type 1 (HI1) Hemorrhage infarction type 2 (HI2) Parenchymal hematoma type 1 (PH1) Parenchymal hematoma type 2 (PH2)
Time Frame
24 hours
Title
Incidence of procedure-related complications such as arterial perforation or dissection, embolization in new territory
Time Frame
48 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years M1-Middle Cerebral Artery occlusion Eligible for mechanical thrombectomy: groin puncture performed within 24 hours from the first symptoms or from the last time the patient was seen normal. Presence of a mismatch on Magnetic resonance imaging MRI or CT (computed tomography) scan Baseline mRS <2 Irregular occlusion phenotype on the first angiographic run Informed consent obtained from the patients/his proxy or following an emergency procedure Being covered by a national health insurance Exclusion Criteria: Isolated M2 occlusions Clinical history, past imaging or clinical judgment suggesting underlying intracranial stenosis Severe contrast medium allergy or absolute contraindication to use of iodinated products Patients with severe or fatal comorbidities that will likely prevent improvement or follow-up, or that will render the procedure unlikely to benefit the patient Angiographic evidence of carotid dissection or tandem cervical occlusion or stenosis requiring treatment Pregnancy (urine or serum beta HCG test for women of child-bearing potential) Patient benefiting from a legal protection (guardianship or curatorship) Being deprived of liberty
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Marthe MAHI
Phone
0033146257387
Email
m.chouakam-jiabe@hopital-foch.com
First Name & Middle Initial & Last Name or Official Title & Degree
Arturo CONSOLI
Phone
0033146251955
Email
a.consoli@hopital-foch.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Arturo CONSOLI
Organizational Affiliation
Foch Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Bertrand LAPERGUE
Organizational Affiliation
Foch Hospital
Official's Role
Study Chair
Facility Information:
Facility Name
Chu Bordeaux
City
Bordeaux
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gaultier MARNAT
Email
Gaultier.marnart@chu-bordeaux.fr
Facility Name
CHU Montpellier
City
Montpellier
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vincent COSTALAT
Email
vincent.costalat@chu-montpellier.fr
Facility Name
Chru Nancy
City
Nancy
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Benjamin GORY
Email
b.gory@chu-nancy.fr
Facility Name
Chu Nantes
City
Nantes
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Romain BOURCIER
Email
romain.bourcier@chu-nantes.fr
Facility Name
APHP - Pitié Salpêtrière
City
Paris
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Frédéric CLARENCON
Email
frederic.clarencon@aphp.fr
Facility Name
Fondation Adolphe de Rothschild
City
Paris
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michel PIOTIN
Email
mpiotin@for.paris
Facility Name
CHU de Reims
City
Reims
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sébastien SOIZE
Email
ssoize@chu-reims.fr
Facility Name
Hôpital FOCH
City
Suresnes
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Arturo CONSOLI
Phone
0033146251955
Email
a.consoli@hopital-foch.com
Facility Name
CHU de Tours
City
Tours
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Grégoire BOULOUIS
Email
g.boulouis@chu-tours.fr

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Stent Retriever Versus Contact Aspiration in Irregular Occlusion Phenotype

We'll reach out to this number within 24 hrs